Effectiveness of Ezetimibe in NAFLD patients with hyperlipidemia

Effectiveness of Ezetimibe in NAFLD patients with hyperlipidemia - Effectiveness of Ezetimibe in NAFLD patients with hyperlipidemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003932

Enrollment

Registered

2010-07-26

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcholic fatty liver disease

Interventions

Ezetimibe 10mg/day diet and exercise

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Non-drinking patient 2 Patients with other origin of hepatitis than NAFLD 3 Patients with NAFLD 4 Patients with hyperlipdemia

Exclusion criteria

Exclusion criteria: 1 Patient with allergy for ezetimibe 2 The following patients with grave hepatic dysfunction when use ezetimibe together with statin a)acute exacerbation of acute hepatitis , chronic hepatitis b)cirrhosis , hepatoma , choloplania(child B or more) 3 Pregnancy , women who may possibly be of pregnant 4 Patients with a history of arteriosclerotic disease 5 Patients with secondary hyperlipidemia, drug-induced dyslipidemia 6 Patients who judged that examination doctor in charge is improper

Design outcomes

Primary

Measure	Time frame
Before and after 6 months of Ezetimibe (10mg/day) to NAFLD patients. We assessed Liver tranceminases and lipid levels.	—

Countries

Japan

Contacts

Public ContactHideki Fujii

Osaka City University Medical School Department of Hepatology

rolahideki@med.osaka-cu.ac.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026